DRRX - DURECT CORP
IEX Last Trade
0.95
0 0%
Share volume: 436
Last Updated: Thu 26 Dec 2024 07:35:04 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$0.95
0.00
0.00%
Fundamental analysis
24%
Profitability
18%
Dept financing
38%
Liquidity
75%
Performance
15%
Performance
5 Days
4.44%
1 Month
3.64%
3 Months
-24.22%
6 Months
-25.95%
1 Year
90.57%
2 Year
-71.72%
Key data
Stock price
$0.95
DAY RANGE
$0.93 - $0.95
52 WEEK RANGE
$0.53 - $1.88
52 WEEK CHANGE
$62.51
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
Company detail
CEO: James E. Brown
Region: US
Website: durect.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: durect.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
DURECT Corporation researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses.
Recent news